Objective: This study evaluated whether the use of a staged Hemodialysis Reliable Outflow (HeRO; Merit Medical, South Jordan, Utah) implantation strategy incurs increased early infection risk compared with conventional primary HeRO implantation.
Patients with end-stage renal disease who require hemodialysis are at risk for development of central venous stenosis or occlusion, with an estimated prevalence of 16% to 50%. [1] [2] [3] Unfortunately, central venous stenosis and occlusions render the ipsilateral extremity suboptimal for surgical access because of the inadequate venous return to the heart, which can result in early or immediate access failure as well as massive and debilitating arm swelling. 4 Therefore, in the setting of known central venous stenosis or occlusion, patients may be required to undergo lower extremity arteriovenous (AV) graft creation vs reliance on a hemodialysis catheter. Hemodialysis catheters are associated with high infection rates, susceptibility to thrombosis, and inconsistent delivery of adequate flow rates, which predisposes patients to increased costs, morbidity, and mortality. 5, 6 The Hemodialysis Reliable Outflow (HeRO) vascular access graft (Merit Medical, South Jordan, Utah) was designed to overcome the limitations of central venous stenosis and occlusions. The HeRO graft consists of an expanded polytetrafluoroethylene graft that connects to a large-caliber silicone venous outflow component (VOC) that courses through the central veins and terminates in the right atrium, thus bypassing any central venous stenoses or occlusions. The HeRO graft is entirely subcutaneous, which is thought to partly account for its lower rates of infection compared with tunneled hemodialysis catheters. 7 HeRO patency rates have been reported to be similar to AV grafts and superior to tunneled hemodialysis catheters. During a conventional primary HeRO graft implantation, the VOC of the HeRO graft is typically inserted via a venous access site created when the graft is implanted and the arterial anastomosis is constructed. However, an existing tunneled hemodialysis catheter can also be used to obtain rapid guidewire access to the right atrium. This can be particularly helpful when there is central venous stenosis or occlusion around the catheter, thus avoiding time, costs, and effort required to regain guidewire access across the occlusion. We term this an "incidentally staged" HeRO insertion, because the tunneled hemodialysis catheter was inserted previously, without a specific plan to be converted to a HeRO graft. In cases of known extensive central venous occlusion without a pre-existing central venous catheter, insertion of a HeRO graft may be extremely difficult or impossible.
Attempting to recanalize an extensive central venous occlusion with plans for subsequent HeRO graft implantation likely represents suboptimal use of the operating room and a dedicated anesthesiology team if extended efforts are undertaken without success. For this reason, planning for a dedicated recanalization attempt as a stand-alone procedure in an optimized setting, potentially by an operator who has particular expertise in venous recanalization, may be preferable. If successful, a tunneled central venous catheter can be inserted across the lesion(s) into the right atrium specifically as a placeholder. Subsequently, in a separate setting on a later date, the HeRO graft can be implanted using the existing catheter for rapid guidewire access to the atrium. We term this an "intentionally staged" HeRO implantation, because the central venous catheter was specifically inserted for planned eventual conversion to a HeRO graft. By doing so, operating room workflow is improved and local expertise can be optimally used.
There may, however, be theoretical concern that implanting a HeRO graft using a potentially colonized catheter tract could result in subsequent HeRO graft infection. Therefore, the purpose of this study was to compare early HeRO graft infection rates when implanted using a primary or staged implantation approach.
METHODS
Institutional Review Board approval was obtained for this retrospective study. A waiver of informed consent was granted. All procedures were performed in the interventional radiology suites under moderate sedation. Preprocedural antibiotics (cefazolin, 1 g; or clindamycin, 1g, if allergic) were administered at the onset of the procedure. Access from the supraclavicular region to the right atrium was achieved using a variety of techniques, including blunt venous recanalization, sharp recanalization, radiofrequency wire recanalization, through-and-through access, and transmediastinal access. Once access to the right atrium was achieved, a catheter exit site was chosen lateral to the access site on the upper chest. A Power Hickman single-lumen central venous catheter was inserted, tunneled to the venous access site, and inserted via a peel-away sheath with the catheter tip located in the right atrium (Fig) .
Primary HeRO implantation technique. HeRO graft implantation was performed in the operating room, with patients under general endotracheal anesthesia, using a combination of open surgical and endovascular techniques, as previously described by Gage et al. 8 Briefly, all patients underwent initial upper extremity vessel mapping and central imaging. Only patients with a significant central venous stenosis or occlusion, or both, as determined by angiography and presence of collateral veins were selected for HeRO implantation. Real-time ultrasound guidance was used to access the internal jugular or subclavian vein with a 21-gauge needle using the Seldinger technique.
After successful guidewire navigation through the central venous system and right atrium into the inferior vena cava, the HeRO VOC was inserted through the venous access site via a peel-away sheath. The VOC was then tunneled laterally to a counter incision near the deltopectoral groove. After arterial exposure was achieved, the expanded polytetrafluoroethylene graft component was tunneled subcutaneously from the arterial exposure to the VOC in the counterincision over the deltopectoral groove. The graft was then tunneled in a superficial straight "soft C" or "teardrop" loop configuration, depending on the arterial inflow location. The VOC was trimmed to the appropriate length, and the two components were coupled at the counterincision using the titanium connector. A standard arterial anastomosis was performed at the target artery to provide inflow for the HeRO graft.
Staged HeRO implantation technique. The staged HeRO implantation technique was used for patients with a pre-existing tunneled central venous catheter. By palpating the course of the catheter, an ideal site for catheter access was chosen remote from the catheter exit site (typically over or near the original venous access site). An incision was made over the catheter, which was dissected free of the surrounding tissues. The catheter was then transected, allowing a guidewire to be advanced through the catheter, across the right atrium, and into the inferior vena cava. The catheter segments were removed and discarded at this point. The HeRO implantation sequence then proceeded as described in the paragraph above.
Definitions. HeRO-related infection was diagnosed by an attending vascular surgeon based on presence of fever, leukocytosis, culture-positive bacteremia, or physical examination findings such as localized erythema, warmth, tenderness, and purulent discharge over the graft site. In all cases, patients were treated with intravenous antibiotics and observed for clinical improvement. If resolution was not achieved, surgical excision was performed. The interval from HeRO implantation to surgical excision was recorded. Episodes of culturepositive bacteremia and the interval from HeRO implantation to culture positivity were recorded.
Early infection was defined as an infectious event occurring #30 days of HeRO implantation, according to the Society for Vascular Surgery reporting standards for AV hemodialysis access. 9 The early infection time was considered to be the most important metric because any colonization of the HeRO graft at the time of implantation related to a colonized catheter tract (as seen with staged HeRO implants) would be expected to manifest as a frank infectious event within this time frame. Infectious events occurring #90 days were also recorded, because some patients with early HeRO-related infection may be suppressed with antibiotics at 30 days and may manifest over the following 2 months. Patient deaths in the setting of sepsis and suspected HeRO infection were also considered as HeRO infections. The overall time-to-resection resulting from HeRO infection was also calculated. The secondary access patency was defined as the interval from implantation until access abandonment or surgical revision.
Statistical analysis. Statistical analysis was performed using SPSS 20 software (IBM Corp, Armonk, NY). Baseline demographics between the primary vs staged implantation groups were compared using the c 2 test for categoric variables and the Student t-test for continuous variables. The occurrence of early HeRO infection was compared between groups using the c 2 test. Predictors of infection were calculated using a univariate linear regression analysis. The interval from HeRO implantation to infection was calculated using the Kaplan-Meier technique. Censored time points included patient death, renal transplantation, HeRO resection not related to infection, or HeRO abandonment. Infection-free intervals were compared using the log-rank test. A P value of <.05 was considered statistically significant.
RESULTS
Analysis of the primary vs staged HeRO implantation groups demonstrated that the staged implantation group had a significantly higher mean body mass index (BMI), a significantly higher incidence of diabetes, a significantly higher incidence of human immunodeficiency virus (HIV), and significantly more frequent insertion on the right side (Table I) . For staged HeRO implantations, the median interval between tunneled catheter insertion and conversion to a HeRO graft was 42 days. The median interval was 16 days in intentionally staged procedures vs 228 days in incidentally staged procedures (P < .001).
The early HeRO-related infection rate (#1 month of implantation) was 8.6% for primary HeRO implantations and 2.3% for staged implantations (P ¼ .12; Table II ). The early bacteremia rate for the primary and staged HeRO implantations was similar between groups: 7.6% vs 2.3%, respectively (P ¼ .19), as was the rate of HeRO infections requiring surgical resection of part or all of the graft: 4.8% vs 0%, respectively (P ¼ .065). Analysis of HeROrelated infection rates for bacteremia and HeRO infection requiring resection at 3 months after implantation also showed no significant differences (Table II) . Subanalysis of the staged implantations demonstrated no significant difference between the intentional vs incidentally staged HeRO implant groups for bacteremia, HeRO infection requiring resection, or any infection (P ¼ .53).
Univariate analysis revealed that none of the following analyzed factors correlated significantly with risk of infection: age, gender, laterality, anastomosis of an existing AV access, interval between catheter insertion and HeRO implantation, primary implantation, diabetes, HIV, ongoing steroid therapy, chemotherapy, or BMI. Patients with a staged HeRO implantation had a longer infection-free interval than those with primary implantations (mean, 63.8 vs 52.5 months; P ¼ .007), with a corresponding infection rate of 0.12 compared with 0.41 infections per 1000 days, respectively.
Median secondary access patency for the HeRO graft was 44.0 months for primary implantation vs 42.9 months for staged implantation (P ¼ 1.0). The number of interventions to maintain secondary patency was similar between primary and staged implantations (0.32 vs 0.96 interventions per 100 implant days; P ¼ .23).
DISCUSSION
Patients with end-stage renal disease and central venous occlusion pose a particularly challenging patient population. Surgical creation of AV access in the upper extremity typically results in debilitating arm swelling or early/immediate access failure, whereas insertion of tunneled central venous catheters into the upper body can be difficult or impossible. Thus, these patients must rely on less optimal hemodialysis access routes such as femoral or transhepatic hemodialysis catheters. The HeRO graft can allow for creation of an upper body AV graft if the central venous occlusion can be traversed. However, the ability and likelihood of recanalizing central venous occlusions varies based on local expertise, experience, physical resources, and time constraints for this often time-consuming procedure.
The strategy used at our institution was developed to optimize work flow and efficiency. If a central venous occlusion was found around an existing hemodialysis catheter, the catheter was used for intraoperative guidewire access. However, if a central venous occlusion was identified without a pre-existing hemodialysis catheter traversing the occlusion, patients were referred to an interventional radiologist with particular expertise in central venous imaging and recanalization as well as optimal equipment and supplies for this procedure. By leaving a tunneled central venous catheter across the recanalized occlusion, HeRO graft implantation can be performed at a later date. On the basis of the very low infection rates with hemodialysis catheters that had been indwelling for a mean of 228 days, there appears to be no reason to minimize the interval between catheter insertion and HeRO implantation. At the time of HeRO implantation, guidewire access can be quickly and conveniently obtained across the stenosis or occlusion. In doing so, the duration of general anesthesia exposure can be minimized because any preceding central venous recanalization procedure is typically performed with moderate sedation. Furthermore, this staged approach will prevent the scenario of an aborted intraoperative HeRO graft implantation due to inability to gain guidewire access across a severe stenosis or occlusion. Thus, a multidisciplinary approach to manage these complex patients can optimize the overall success rate of HeRO implantation in catheterdependent patients.
Despite theoretical concern for an increase in HeRO graft infection with the staged HeRO implantation approach, the current study demonstrated no increased early infection risk compared with the conventional primary HeRO implantation technique during the time frame when surgical site contamination related to a prior catheter tract would cause HeRO graft infection. Among the staged HeRO implantations, there was no significant difference in the short-term infection rates between incidentally indwelling hemodialysis catheters vs tunneled catheters inserted specifically for HeRO implantation, even though the median catheter indwell time was nearly 1 year for the hemodialysis catheter group. Furthermore, of the analyzed infection-related risk factors, a high BMI, diabetes mellitus, and HIV were significantly more prevalent in the staged implantation group, although none of the analyzed variables significantly affected the early infection rate on univariate analysis. The rate of HeRO infection requiring resection for primary and staged HeRO implantations was 0.41 and 0.12 infections per 1000 implant days, respectively, which was significantly lower for the staged implantation group. This rate of infection lies within the reported range of HeRO-related infections at 0.14 to 0.70 infections per 1000 implant days. 8, [10] [11] [12] Interestingly, the staged implants were associated with a significantly lower infection rate compared with the primary implantation, despite the theoretical concern for an increased infection risk. We are uncertain about the etiology of the lower infection rate in the staged HeRO implantation group, although it may be related to an unaccounted-for confounding variable. However, as mentioned, the goal of the study was to determine whether implanting a HeRO graft in continuity with a potentially colonized subcutaneous tract from a prior tunneled catheter affects early HeRO infection rates. This finding is thus of uncertain pertinence to our primary goal, because AV graft and catheter infection is a common occurrence that typically results from causes unrelated to implantation technique such as needle puncture contamination or seeding by bacteremia from an alternative source. The primary limitation of this study is its retrospective nature. Thus, it is prone to selection bias, which may account for some of the differences. Assessment of infection risk with primary vs staged HeRO implantation would be best ascertained in a randomized fashion. Another limitation is the complexity of diagnosing graft or outflow component infection. Finally, because this study is based on a data from a single center, relevant patient care at other hospitals may not have been captured.
CONCLUSIONS
The use of a staged HeRO implantation strategy did not result in an increased infection risk compared with the conventional primary HeRO implantation technique. Therefore, the use of an existing tunneled hemodialysis catheter for intraoperative venous access for the HeRO graft is an efficient and safe strategy. Furthermore, the intentionally staged approach, including the use of a multidisciplinary team to capitalize on expertise and resources, is also safe and effective and may optimize rates of successful HeRO implantation and minimize the number of patients with hemodialysis catheters as their only option for access.
